Tag: immunotherapy

‘A new narrative’: TACE in the age of Y90 and immunotherapy

Hotly debated across the Society of Interventional Oncology (SIO; 25–29 January 2024, Long Beach, USA) annual conference programme, speakers took to the stage to...
hepzato

Delcath Systems announces updated results from CHOPIN phase 1b trial

Delcath Systems has shared in a press release the publication of updated results from the phase 1b CHOPIN Trial, conducted at Leiden University Medical...
trisalus

TriSalus presents preclinical data on proprietary infusion technology at SIR 2022

TriSalus’ clinical leadership team presented new preclinical data at the Society of Interventional Radiology (SIR) 2022 Annual Scientific Meeting (11–16 June, Boston, USA). The...

AB-LATE02 randomised trial to probe “synergistic” immunotherapy and ablation strategy for...

A randomised trial—AB-LATE02—will assess the efficacy of a combination of neoadjuvant atezolizumab, and adjuvant atezolizumab and bevacizumab with radiofrequency ablation (RFA) as a treatment...

US FDA grants Breakthrough Therapy Designation for combination immunotherapy in HCC...

Roche has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq (atezolizumab) in combination with Avastin (bevacizumab)...

Guerbet announces Lausanne partnership to evaluate immunogenic potential of cTACE

Guerbet has announced a partnership with the Department of Radiodiagnosis and Interventional Radiology of Lausanne's University Hospital (CHUV) and the Lausanne Center for Experimental...
Interventional News for specialists

Targeted immunotherapy treatment shows promise for treating for advanced liver cancer

Advanced stage liver tumours may be safely treated through image-guided injections of an immunotherapy approved for melanoma, according to phase 1 data presented at...

ECR 2018: Will immunotherapy revolutionise cancer care?

Evasion of the immune system is an important mechanism in the development and progression of cancers. Cancer immunotherapies are a promising class of therapeutic...

Surefire Medical appoints Mary T Szela CEO and president

Szela brings nearly 30 years of progressive leadership experience to Surefire building global billion-dollar brands, advancing pipeline products in the biotechnology, medical products, and...
Interventional News for specialists

BTG and SIO expand Immuno-Oncology / Interventional Oncology grant programme

BTG and the Society of Interventional Oncology (SIO) have expanded their commitment to the Immuno-oncology /interventional oncology research grant programme, by announcing a second...

Identification of pancreatic cancer pathway could broach new era of effective...

Pancreatic Cancer Action Network (PanCAN) grantee George Miller, head of the Cancer Immunology Program at Perlmutter and vice chair for research in the Department...

Hitting cancer with high-intensity ultrasound and immunotherapy

In a new study published in JCI Insight, UC Davis researchers have shown that combining high-intensity focused ultrasound with two immunotherapies (a PD-1 checkpoint...

Interventional oncology should identify “unmet immunotherapy needs”

Daniel Sze, speaking at the ninth annual Symposium on Clinical Interventional Oncology (CIO; 4–5 February 2017, Hollywood, USA), noted that immunotherapy is a “huge...

Adding interventional oncology to immuno-oncology

Some research data suggest there could be a synergistic effect between immunotherapy and minimally invasive procedures. Tumour types that do not respond to checkpoint...

BTG and SIO to explore role of minimally invasive therapies in...

BTG has announced a collaboration with the Society of Interventional Oncology (SIO; a global organisation working to nurture and support interventional oncology worldwide) to...